Study of growth, metabolism, and morphology of *Akkermansia muciniphila* with

an *in vitro* advanced bionic intestinal reactor

Zhi-tao Li[a], Guo-ao Hu[a], Li Zhu[b], Zheng-long Sun[c], Yun-Jiang, Min-jie Gao[a*], Xiao-bei Zhan[a*]

[a] Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of

Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China

[b] Wuxi Galaxy Biotech Co. Ltd., Wuxi 214125, China

[c] Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of

Sciences, Suzhou 215163, China

*Corresponding authors:

Tel: +86 510 85918299

E-mails: gaominjie@msn.com (Min-jie Gao)

xbzhan@yahoo.com (Xiao-bei Zhan)

Abstract:

As a kind of potential probiotic, *Akkermansia muciniphila* abundance in human body is directly causally related to obesity, diabetes, inflammation and abnormal metabolism. In this study, *A. muciniphila* dynamic cultures using five different media were implemented in an *in vitro* bionic intestinal reactor for the first time instead of the traditional static culture using brain heart infusion broth (BHI) or BHI + porcine mucin (BPM). The biomass under dynamic culture using BPM reached 1.92 g/L, which improved 44.36% compared with the value under static culture using BPM. The biomass under dynamic culture using human mucin (HM) further increased to the highest level of 2.89 g/L. Under dynamic culture using porcine mucin (PM) and HM, the main metabolites were short-chain fatty acids (acetic acid and butyric acid), while using other media, a considerable amount of branched-chain fatty acids (isobutyric and isovaleric acids) were produced. Under dynamic culture Using HM, the cell diameters reached 999 nm, and the outer membrane protein concentration reached the highest level of 26.26 μg/mg. This study provided a preliminary theoretical basis for the development of *A. muciniphila* as the next generation probiotic.

Keywords: *Akkermansia muciniphila,* anaerobic fermentation, bioreactor, short-chain fatty acids

1. Introduction

In recent years, the research and the development of *Akkermansia muciniphila* has attracted interest[1-5]. *A. muciniphila* is an elliptical, immobile, strictly anaerobic Gram-negative strain that can use mucin in the intestine as carbon, nitrogen, and energy sources for growth[6]. The main metabolite of *A. muciniphila* are short-chain fatty acids (SCFAs) and branched-chain fatty acids (BCFAs) [7-10]. *A. muciniphila* was considered as a potential probiotic because evidences proved that *A. muciniphila* had a causal relationship with obesity[11-14], diabetes[15-17], inflammation[18-19], autism[20-21], amyotrophic lateral sclerosis[22], premature aging[23], epilepsy[24], hypertension[25], cancer[26] and metabolic abnormalities[27]. Recent studies reported that butyric acid produced by intestinal microbes like *A. muciniphila* could promote β cells to secrete insulin and then regulate blood sugar[28]. In addition, *A. muciniphila* cells with thicker outer membrane protein (Amuc-1100) showed better effects in preventing obesity and related complications[14].

In terms of *in vitro* culture of *A. muciniphila*, the traditional way was to use brain heart infusion broth (BHI) or BHI + porcine mucin (BPM) in an anaerobic bottle and placed it in an anaerobic environment for static fermentation culture[29-31]. Porcine mucin (PM) was the key component of *A. muciniphila* media in most reports. By adding a certain amount of mucin to BHI to cultivate *A. muciniphila*, the nutritional requirements for its growth and metabolism could be met. For simulation of *A. muciniphila* physiological state in human body, using human mucin (HM) instead of PM for *in vitro* culture is one key issue of great significance. However, as far as we know, the *in vitro* culture of *A. muciniphila* using HM has not been reported yet.

For culture method, the currently used *A. muciniphila* static culture is easy to cause

accumulation of metabolites, which in turn inhibits the growth of *A. muciniphila.* In addition,

A. muciniphila cells are difficult to harvest because many of them adhere to bottle bottom and

wall. The *in vitro* dynamic fermentation reactor is a recently developed tool for studying the

intestinal flora, mainly through bionic technology to simulate the real environment in

digestive system [32]. In this study, an advanced bionic intestinal reactor (ABIR) was built to

simulate the peristalsis of the real human colon, the micro-ecological environment of

intestinal and the absorption of flora metabolites. As the traditional static culture state is far

from the real *A. muciniphila* growth environment in human body, using ABIR as the *A.*

muciniphila culture equipment is another key issue of great significance for simulating *in vivo*

A. muciniphila physiological environment.

In this study, in order to better understand the growth, metabolism and morphology of *A.*

muciniphila in real human body, *in vitro* dynamic *A. muciniphila* fermentation was

implemented using five different media including HM and BHI + human mucin (BHM) in

ABIR. The discovery was an improvement in culture method and media for the development

of *A. muciniphila* as the next generation probiotic.

2. Materials and Methods

2.1 . Strains and media

2.1.1 Strains

A. muciniphila DSM 22959 was purchased from the German Collection of

Microorganisms and Cell Cultures.

2.1.2 Medium preparation

The BHI contained 10.0 g/L tryptone, 2.5 g/L dibasic sodium phosphate, 17.5 g/L BHI,

5.0 g/L sodium chloride, and 2.0 g/L glucose and was maintained at pH 6.5

The PM contained 4 g/L porcine mucin, 2.5 g/L disodium hydrogen phosphate, and 5.0

g/L sodium chloride and was maintained at pH 6.5(porcine mucin, Kuer, Beijing)

The HM contained 4 g/L human mucin, 2.5 g/L disodium hydrogen phosphate, and 5.0

g/L sodium chloride and was maintained at pH 6.5 (human mucin, extracted from pancreatic

myxoma)

The BPM contained 10.0 g/L tryptone, 2.5 g/L disodium hydrogen phosphate, 17.5 g/L

bovine heart dip powder, 5.0 g/L sodium chloride, 2.0 g/L glucose, and 4 g/L pig-derived

mucin and was maintained at pH 6.5

The BHM contained 10.0 g/L tryptone, 2.5 g/L disodium hydrogen phosphate, 17.5 g/L

bovine heart dip powder, 5.0 g/L sodium chloride, 2.0 g/L glucose, and 4 g/L human mucin

and was maintained at pH 6.5

All media had the same concentration, magnetically stirred for 2 h, mixed well, and

sterilized at 121°C for 30 min before use（Mucins remove bacteria through a filter

membrane）.

2.2. Cultivation method

2.2.1 Device introduction

An *in vitro* ABIR was developed to simulate the environment of *A. muciniphila* in the

real large intestine[33]. As shown in Figure 1, the bioreactor was composed of three

interconnected reaction bottles with a flexible and transparent silica gel intestine that

simulated the internal intestinal wall and the shape of the bionic intestine. The silica gel

membrane between the reaction flask and the large intestine (Figure 1d) was filled with

deionized water at 37 °C. The simulated large intestine contracted and caused peristaltic

waves by on line controlling the pressure of the water flow through a circulating water pump.

Thus, the materials in the simulated large intestine were mixed and moved in the system. This

mixing was better than the mixing done in the fermenter, where the phase separation of fluid

and solid occurred. The reaction bottle was equipped with vacuum (Figure 1g) and mixed gas

(Figure 1h) control devices to continuously maintain the oxygen-free environment in the

simulation chamber. The system was also added with a water absorption device that simulated

the function of the large intestine (Figure 1j). The mixture in the cavity was absorbed to

simulate the formation of feces. By continuously measuring the pH (Figure 11) and secreting

alkaline solution (Figure 1e) to neutralize the acid, the system pH was maintained to prevent

the accumulation of microbial metabolites. The system was equipped with a dialysis device,

which consisted of hollow fiber nanofiltration membranes that filtered the metabolic products

of microorganisms. Thus, the microbial metabolites in the reactor cavity were maintained at

physiological concentrations.

2.2.2 Dynamic and static culture methods

The specific operation under dynamic culture was as follows. At first, the air tightness of

the system was checked, and the whole reactor was immersed in water. The mixed gas aerator

was opened to fill the reactor cavity with gas. If no bubble emerged, the air tightness of the

system was good. The connection seals of each reaction bottle were detected to ensure that no

bubble emerged. An aliquot of frozen stock culture of *A. muciniphila* (100 μL) was inoculated

in 5 mL medium and incubated at 37 °C for 24 h under strict anaerobic conditions (hydrogen,

5%; carbon dioxide, 10%; nitrogen, 85%). The configured medium was added into the ABIR

through the sample port, placed in a sterilization pot maintained at 121 °C for 30 min, and

cooled to 37 °C. The extraction valve was opened, and the air in the reactor was extracted.

The extraction valve was closed, and the inflation valve was opened. Anaerobic gas

(hydrogen, 5%; carbon dioxide, 10%; nitrogen 85%) was poured into the reactor, and the

process was repeated thrice for the reactor to have an anaerobic environment. The seed fluid

flow of the incubated strain was added to the reactor cavity through a peristaltic pump. The

reactor peristaltic system and the dynamic cultivation of the strain were started. In addition,

the OD_{600} module (Figure 1m) can be added to this reactor to monitor the OD_{600} value of the

fermentation broth in real time. For static culture, the same cultured seed liquid (5 mL) was

transferred to an anaerobic bottle with BPM medium volume of 300 mL. The culture was

carried out by static incubation for 48 h under the same conditions.

2.2.3 Biomass determination

The fermentation broth (10 mL) was collected and centrifuged, washed twice with

deionized water, moved to the centrifuge tube after weighed, and centrifuged to obtain the

cells. The cells were dried at 105 °C and weighed[34].

2.2.4 Determination of the short-chain fatty acids of metabolites

The fermentation broth (1 mL) was collected, added with 10 μL 2-methylbutyric acid (1

M) as an internal standard, and slowly added with 250 μL concentrated hydrochloric acid. The

mixture was mixed well, added with 1 mL diethyl ether, vortexed for 1 min, and allowed to

stand until the organic and the water phases separated. The supernatant (organic phase) was

carefully collected, added with anhydrous sodium sulfate, vortexed, and passed through a

0.22 μm organic filter. The supernatant (5 μL) was injected into the Agilent 7890 gas

chromatograph equipped with an electron capture detector (Agilent, USA), which was used to

determine the short-chain fatty acids of *A. muciniphila*.

The gas chromatographic conditions were as follows: instrument, Agilent-7890A;

chromatography column, HP-INNOWAX; detector temperature, 250 °C; inlet temperature,

220 °C; flow rate, 1.5 mL/min; split ratio, 1:20; heating program, 60 °C–190 °C, 4 min; and

injection volume, 5 μL.

2.2.5 Bacterial outer membrane protein extraction method and concentration determination

A. muciniphila was subjected to outer membrane protein extraction using the bacterial

outer membrane protein extraction kit (BIOLABO HR0095, Beijing), and the protein content

was estimated using the enhanced BCA protein assay kit (Beyotime Biotechnology, Beijing).

2.2.6 FSEM and FTEM

The cultured strains were washed with PBS buffer; fixed with 2.5% glutaraldehyde

solution at 4 °C for 2 h; washed again with PBS buffer; dehydrated using 30%, 50%, 70%,

80%, 90%, and 100% alcohol; dried; sprayed with gold; and lyophilized using the SU8200

(Japan) equipment. FSEM analysis was performed, and the morphology of *A. muciniphila*

was observed at 3.0 KV×10.0k. The cell suspension was dropped on the copper grid and then

dried at room temperature. TEM observations were taken by a transmission electronic

microscope (JEM-I010, Hitachi, Tokyo, Japan) in 120 kV.

2.2.7 A. muciniphila outer membrane relative thickness and diameter measurement

The TEM and SEM images were imported into the Adobe Photoshop CC 20.0.4, and the

ruler tool was used to measure the relative thickness and diameter of the adventitia. Each cell

was measured four times at different locations and the averaged values were presented.

2.2.8 Statistical analysis

Data were expressed as mean ± SEM. Differences between the two groups were assessed

using the unpaired two-tailed Student t test. The data sets that involved more than two groups

were assessed using ANOVA. In the figures, data with * were significantly different at $P <$

0.05 in accordance with posthoc ANOVA. Data were analyzed using the GraphPad Prism

version 8.00 for Windows (GraphPad Software).

Statistical comparisons were indicated with *, **, and *** for $P < 0.05$, $P < 0.01$, and $P <$

0.001, respectively.

3. Results and Discussion

3.1 Effects on cell growth and metabolites of A. muciniphila under static and dynamic

cultures

The static culture and ABIR dynamic culture were compared in terms of biomass and

metabolites. Compared with the static culture, the ABIR simulated physic-chemical and

physiological processes in the real human colon, which was an idea tool for investigating the

effects of the media components on *A. muciniphila* fermentation. As shown in Figure. 2a, the

logarithmic growth periods of static cultures and ABIR dynamic culture were both 6–10 h,

then the bacteria entered a stable stage after 12 h. The biomass under the ABIR dynamic

culture increased steadily after 37 h and reached 1.92 g/L at 48 h, which was 44.36% higher

than that of the static culture (1.33 g/L). In static culture, the metabolites of *A. muciniphila*

accumulated partially at the late stage of the culture process and high level of SCFAs (> 80

mM) inhibited cell growth [8, 35]. In ABIR dynamic culture, simulation of real human colon

peristalsis was achieved, and the cells, media and metabolites could be well mixed. Thus, the

inhibition effects of metabolites could largely be released. For both static and dynamic

cultures, the type and concentration of metabolites were shown in Figure. 2b. Under dynamic

culture, the metabolites were mainly acetic acid, propionic acid, butyric acid, isobutyric acid,

and isovaleric acid yields, which reached 47.05, 10.21, 9.87, 2.78, and 4.06 mM, respectively.

The differences in yields of butyric acid between two cultures were significant ($p<0.05$).

Simultaneously, considerable differences were observed in terms of yields of propionic acid,

isobutyric acid and isovaleric acid ($p<0.01$). Under dynamic culture, isobutyric acid and

isovaleric acid yields were relatively higher than those under static culture. In the late

fermentation stage of dynamic culture, the carbon source was exhausted and *A. muciniphila*

turned to protein fermentation, thereby generated corroded toxic metabolites, such as

isobutyric acid and isovaleric acid[36-37].

3.2 Effects of different media on A. muciniphila growth under dynamic culture

Using five different media (BHI, PM, HM, BPM and BHM)*, A. muciniphila* biomass

under dynamic cultures were compared. The mucin in the PM and HM were the only carbon

and nitrogen sources for the growth of *A. muciniphila*. When *A. muciniphila* grew on these

media, glycosidase was secreted to degrade the glycoprotein exposed at the terminal of mucin

to produce N-acetylgalactosamine, N-acetylglucosamine, fucose, and galactose components,

which could be used as nutrients for cells[38-40]. As shown in Figure 3a, using PM and HM,

A. muciniphila grew slowly at 0–18 h, and the biomass of *A. muciniphila* grown on PM (0.68

g/L) was higher than that on HM (0.35 g/L). During this period, the secretion rates of

glycosidase and protease accelerated, resulting in increased degradation of mucin. After this

period, *A. muciniphila* adapted to the growth environment of medium. The growth rates of *A.*

muciniphila on PM and HM were both in the logarithmic period from 18 h to 36 h. From

36–48 h, the biomass of *A. muciniphila* on HM exceeded that on PM and reached 2.89 g/L at

48 h. The results proved that *A. muciniphila* culture medium based on human mucin was an

ideal medium for cell growth. Moreover, growth performances of *A. muciniphila* on BHI,

BPM, and BHM were studied. As shown in Figure 3b, the *A. muciniphila* grown on BPM and

BHM were in logarithmic growth phase at 4–8 h, and the *A. muciniphila* biomass on BPM

(1.26 g/L) was higher than that on BHM (0.85 g/L). The *A. muciniphila* grown on BHI was in

the logarithmic growth phase at 8–12 h, and *A. muciniphila* biomass of 0.61 g/L was obtained,

which was lower than that on BPM and BHM. All three batches subsequently entered a stable

growth phase. At 48 h, the biomass on BHI, BPM, and BHM were 1.17, 1.92, and 1.96 g/L,

respectively. The BHI contained rich carbon and nitrogen sources, which supposed to fully

support the growth of *A. muciniphila*. However, the biomass on BHI was the lowest among

the three batches. When mucin was added in BHI, the biomass of *A. muciniphila* increased

about 65%, which demonstrated that mucin was a key component for *A. muciniphila* growth.

To find other cheaper sources instead of mucin, Derrien and Colleagues discovered that *A.*

muciniphila could also grow on a limited amount of carbon source, including

N-acetylglucosamine, N-acetylgalactosamine, and glucose[6, 31]. Based on this, a mixed

medium instead of mucin to cultivate *A. muciniphila* was formed by adding glucose, soy

protein, threonine, N-acetylglucosamine and N-acetylgalactosamine together. The biomass of

A. muciniphila grown on the mixed medium reached the same level of the batches grown on

BPM or BHM[14, 41]. In addition, studies found that adding fructooligosaccharides[42-43],

metformin[44-45], polyphenols[46-49], probiotics[50-51] and fish oil unsaturated fatty

acids[52] could increase the abundance of *in vivo A. muciniphila*.

3.3 Effects of different media on A. muciniphila metabolites under dynamic culture

Using five different media, the type and the concentration of *A. muciniphila* metabolites

(SCFAs and BCFAs) were further studied, and an interesting conclusion was obtained, as

shown in Figure 4. The metabolites of *A. muciniphila* on PM and HM were SCFAs (acetic

acid and butyric acid), whereas the metabolites of *A. muciniphila* on BHI, BPM, and BHM

were SCFAs (acetic, propionic, butyric, valeric) and BCFAs (isobutyric and isovaleric acids).

For the batches grown on PM and HM, the concentrations of acetic acid (4–6 mM) were not

significantly different (Figure 4b), but the concentrations of butyric acid were significantly

different (Figure 4a, $P < 0.05$). The concentrations of butyric acid reached 1.06 mM (batch on

HM) and 0.68 mM (batch on PM). For the batches grown on BHI and BHM, the

concentrations of acetic acid (50.43 mM and 22.81 mM) were significantly different ($P<0.05$)

(figure 4c). The concentrations of isobutyric acid (3.15 mM and 2.88 mM) were significantly

different (figure 4e, $P<0.05$). The concentrations of isovaleric acid (4.25 mM and 4.07 mM)

were significantly different (figure 4g, $P<0.05$). The concentrations of valeric acid were very

significantly different (figure 4h, $P<0.001$). For the batches grown on BHI and BPM, the

concentrations of valeric acid were very significantly different ($P<0.01$). For the batches

grown on BPM and BHM, the concentrations of valeric acid were very significantly different

($P<0.05$). For the batches grown on BHI, BPM and BHM, the concentrations of propionic

acid were no significant difference (figure 4d, $P>0.05$). The concentrations of butyric acid

(5.79 mM, 9.88 mM and 12.88 mM) were significantly different (figure 4f, $P<0.05$). The

concentrations of valeric acid (0.14 mM, 0.41 mM, and 0.51 mM) were significantly different

(figure 4h, P<0.01). Studies showed that BCFAs like isobutyrate acid and isovalerate acid,

were derived from the fermentation of branched-chain amino acids. In contrast to straight

chain SCFAs, these compounds were considered detrimental to colonic and metabolic health

[53-54]. Compared with SCFAs, these compounds were considered harmful to the colon and

metabolic health. Isobutyric acid and isovaleric acid were produced on BHI, BPM and BHM.

The contents of butyric acid and valeric acid on BPM and BHM were relatively high,

indicating that the mucin or mucin used by *A. muciniphila* was used simultaneously with

glucose. The latest research showed the causal relationship between the butyric acid produced

by intestinal microorganisms and the risk of diabetes[28]. Butyric acid can promote the

secretion of insulin by β cells, regulate blood sugar, and improve insulin response[36-37].

Further research was needed on the mechanism of *A. muciniphila* main metabolites (acetic

acid and butyric acid) on PM and HM.

3.4 Effects of different media on the concentration of outer membrane protein under dynamic

culture

Outer membrane protein of *A. muciniphila* had a specific protein named Amuc_1100,

which can maintain a stable state at the temperature of pasteurization and improve the

intestinal barrier[14]. Through daily quantitative *A. muciniphila* feeding to mice, *A.*

muciniphila can offset the increase in body weight and fat caused by high-fat diet (HFD) and

improve glucose tolerance and insulin resistance, indicating that Amuc_1100 from

pasteurization *A. muciniphila* outer membrane protein had beneficial effects on HFD-induced

metabolic syndrome. Using five different media, we quantitatively detected the content of the

outer membrane protein of *A. muciniphila*. As shown in Figure 5, the outer membrane protein

concentrations of *A. muciniphila* in the batches grown on BHI, PM, HM, BPM, and BHM

were 17.03, 24.36, 26.26, 18.34, and 19.45 μg/mg, respectively. Significant differences were

observed between the batches grown on BHI and BPM ($P < 0.05$), BHI and BHM ($P < 0.05$),

PM and HM ($P < 0.05$), PM and BHM ($P < 0.05$), BHI and PM ($P < 0.01$), HM and BHM (P

< 0.01), BHI and HM ($P < 0.001$), PM and BPM ($P < 0.001$), and HM and BPM ($P < 0.001$).

Results showed the concentration of the outer membrane protein significantly increased in the

batches grown on media containing only PM or HM. For these batches, the Amuc_1100

protein of *A. muciniphila* increased accordingly. The result provided an alternative way for

the improvement of Amuc_1100 protein content of *A. muciniphila* outer membrane.

3.5 Effects of different media on the thickness of A. muciniphila outer membrane and diameter

of cell under dynamic culture

Figure 6 showed the TEM and SEM images of *A. muciniphila* using five different culture

media under dynamic culture. The cells of *A. muciniphila* were round or elliptical. The cells

of the batch grown on BHI grew alone or in pairs, whereas the cells of the batches grown on

PM, HM, BPM, and BHM containing mucin grew in pairs or chains and even formed

aggregates. Derrien et al. found that using porcine mucin medium under static culture[6], *A.*

muciniphila could grow in single cells or in pairs and rarely grow in chains; it usually forms

aggregates, and a translucent layer of material could be observed. Using BHI, this

phenomenon was rarely observed, and cells appeared alone or in pairs but rarely in

groups[31]. As shown in Table 1, the relative thicknesses of the outer membranes of *A.*

muciniphila in the BHI, PM, HM, BPM, and BHM were 71.66, 101.20, 104.50, 71.46, and

72.11 nm, respectively. Significant differences were observed between the batches grown on

BHI and PM (P < 0.05), PM and BPM (P < 0.05), PM and BHM (P < 0.05), BHI and HM (P <

0.01), HM and BPM (P < 0.01), and HM and BHM (P < 0.01). No significant difference was

observed in the other remaining groups (P>0.05). The above results were consistent with

those of the outer membrane protein concentration of *A. muciniphila*, indicating that increased

outer membrane thickness of the cells resulted in high outer membrane protein concentration.

The cell diameters of *A. muciniphila* grown on BHI, PM, HM, BPM, and BHM were 871, 985,

999, 980, and 971 nm, respectively. The cell diameter on BHI was significantly different with

those on the other four media (P < 0.05), and no significant difference was observed between

the other groups (P>0.05). Derrien et al. found that the cell size differed depending on the

medium under static culture[6, 31]. On the mucin medium, *A. muciniphila* had a diameter and

length of 640 and 690 nm, respectively. On BHI medium, *A. muciniphila* had a diameter and

length of 830 nm and 1000 nm, respectively. The results were different from our discoveries

because of the culture methods (the dynamic culture was carried out in this study).

4 Conclusion

This study firstly compared *A. muciniphila* static culture in an anaerobic bottle and

dynamic culture in the new biomimetic bioreactor. The *A. muciniphila* cell growth under

dynamic culture improved 44.36% compared with the value under static culture using same

medium. Then, the growth status, metabolites, and morphology of *A. muciniphila* under

dynamic culture were further explored using five different media. The biomass of *A.*

muciniphila grown on HM was the highest at 2.89 g/L, followed by that grown on PM, which

indicated that mucin was an essential component for *A. muciniphila* growth. The metabolites

of *A. muciniphila* in batches grown on PM and HM were acetic acid and butyric acid, and the

main metabolites on BHI, BPM and BHM were acetic acid, propionic acid, isobutyric acid,

butyric acid, isovaleric acid, and valeric acid. Among them, butyric acid and valeric acid on

BPM and BHM were significantly different from those on BHI. The appearance of *A.*

muciniphila is round or oval. The outer membrane protein concentrations of *A. muciniphila*

on HM and PM were 35%–40% higher than that on the other three media. The relative

thickness of *A. muciniphila* outer membrane was positively correlated with the concentration

of the outer membrane protein. The diameter of *A. muciniphila* grown on BHI was the

smallest (871 nm), and no significant difference in size of cells grown on the other media was

observed.

Authors' contributions

Conceived and designed research: Min-jie Gao, Zhi-tao Li and Xiao-bei Zhan. Performed the

experiments: Zhi-tao Li, Guo-ao Hu, Li Zhu and Yun Jiang. Analyzed the data: Min-jie Gao,

Zhi-tao Li and Xiao-bei Zhan. Contributed reagents/materials/analytical tools: Zhi-tao Li,

Zheng-long Sun, Min-jie Gao and Xiao-bei Zhan. All authors have read and approved the

final manuscript for publication.

Acknowledgements

This research was supported by National Key Research and Development Program of

China (2017YFD0400302), Fundamental Research Funds for Central Universities

(JUSRP51504, JUSRP51632A), and Jiangsu Province Modern Agriculture Key Project

(BE2018367) and the Priority Academic Program Development of Jiangsu Higher Education

Institutions, the 111 Project (No. 111-2-06) is gratefully acknowledged.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or

financial relationships that could be construed as a potential conflict of interest.

References

[1] Cani, P. D.; de Vos, W. M., Next-Generation Beneficial Microbes: The Case of Akkermansia
muciniphila. *Front Microbiol* **2017,** *8*, 1765.

[2] Zhai, Q.; Feng, S.; Arjan, N.; Chen, W., A next generation probiotic, Akkermansia muciniphila. *Crit.*
Rev. Food Sci. Nutr. **2019,** *59* (19), 3227-3236.

[3] Zhang, T.; Li, Q.; Cheng, L.; Buch, H.; Zhang, F., Akkermansia muciniphila is a promising
probiotic. *Microb Biotechnol* **2019,** *12* (6), 1109-1125.

[4] van der Ark, K. C. H.; Aalvink, S.; Suarez-Diez, M.; Schaap, P. J.; de Vos, W. M.; Belzer, C.,
Model-driven design of a minimal medium for Akkermansia muciniphila confirms mucus adaptation.
Microb Biotechnol **2018,** *11* (3), 476-485.

[5] Zhou, K., Strategies to promote abundance of Akkermansia muciniphila, an emerging probiotics in
the gut, evidence from dietary intervention studies. *J Funct Foods* **2017,** *33*, 194-201.

[6] Derrien, M.; Vaughan, E. E.; Plugge, C. M.; de Vos, W. M., Akkermansia muciniphila gen. nov., sp.
nov., a human intestinal mucin-degrading bacterium. *Int. J. Syst. Evol. Microbiol.* **2004,** *54* (Pt 5),
1469-76.

[7] Le Poul, E.; Loison, C.; Struyf, S.; Springael, J. Y.; Lannoy, V.; Decobecq, M. E.; Brezillon, S.;
Dupriez, V.; Vassart, G.; Van Damme, J.; Parmentier, M.; Detheux, M., Functional characterization of
human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. *J. Biol.*
Chem. **2003,** *278* (28), 25481-9.

[8] Koecher, K. J.; Noack, J. A.; Timm, D. A.; Klosterbuer, A. S.; Thomas, W.; Slavin, J. L., Estimation
and interpretation of fermentation in the gut: coupling results from a 24 h batch in vitro system with
fecal measurements from a human intervention feeding study using fructo-oligosaccharides, inulin,
gum acacia, and pea fiber. *J. Agric. Food Chem.* **2014,** *62* (6), 1332-1337.

[9] Jonathan, M. C.; van den Borne, J. J. G. C.; van Wiechen, P.; Souza da Silva, C.; Schols, H. A.;
Gruppen, H., In vitro fermentation of 12 dietary fibres by faecal inoculum from pigs and humans. *Food*
Chem. **2012,** *133* (3), 889-897.

[10] Holck, J.; Hjernø, K.; Lorentzen, A.; Vigsnæs, L. K.; Hemmingsen, L.; Licht, T. R.; Mikkelsen, J.
D.; Meyer, A. S., Tailored enzymatic production of oligosaccharides from sugar beet pectin and
evidence of differential effects of a single DP chain length difference on human faecal microbiota
composition after in vitro fermentation. *Process Biochem.* **2011,** *46* (5), 1039-1049.

[11] Chassaing, B.; Koren, O.; Goodrich, J. K.; Poole, A. C.; Srinivasan, S.; Ley, R. E.; Gewirtz, A. T.,
Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome.
Nature **2015,** *519* (7541), 92-6.

[12] Dao, M. C.; Everard, A.; Aron-Wisnewsky, J.; Sokolovska, N.; Prifti, E.; Verger, E. O.; Kayser, B.
D.; Levenez, F.; Chilloux, J.; Hoyles, L.; Consortium, M. I.-O.; Dumas, M. E.; Rizkalla, S. W.; Dore, J.;
Cani, P. D.; Clement, K., Akkermansia muciniphila and improved metabolic health during a dietary
intervention in obesity: relationship with gut microbiome richness and ecology. *Gut* **2016,** *65* (3),
426-36.

[13] Everard, A.; Belzer, C.; Geurts, L.; Ouwerkerk, J. P.; Druart, C.; Bindels, L. B.; Guiot, Y.; Derrien,
M.; Muccioli, G. G.; Delzenne, N. M.; de Vos, W. M.; Cani, P. D., Cross-talk between Akkermansia
muciniphila and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A* **2013,**
110 (22), 9066-71.

[14] Plovier, H.; Everard, A.; Druart, C.; Depommier, C.; Van Hul, M.; Geurts, L.; Chilloux, J.; Ottman,

N.; Duparc, T.; Lichtenstein, L.; Myridakis, A.; Delzenne, N. M.; Klievink, J.; Bhattacharjee, A.; van der Ark, K. C.; Aalvink, S.; Martinez, L. O.; Dumas, M. E.; Maiter, D.; Loumaye, A.; Hermans, M. P.; Thissen, J. P.; Belzer, C.; de Vos, W. M.; Cani, P. D., A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat. Med.* **2017,** *23* (1), 107-113.

[15] Qin, J.; Li, Y.; Cai, Z.; Li, S.; Zhu, J.; Zhang, F.; Liang, S.; Zhang, W.; Guan, Y.; Shen, D.; Peng, Y.; Zhang, D.; Jie, Z.; Wu, W.; Qin, Y.; Xue, W.; Li, J.; Han, L.; Lu, D.; Wu, P.; Dai, Y.; Sun, X.; Li, Z.; Tang, A.; Zhong, S.; Li, X.; Chen, W.; Xu, R.; Wang, M.; Feng, Q.; Gong, M.; Yu, J.; Zhang, Y.; Zhang, M.; Hansen, T.; Sanchez, G.; Raes, J.; Falony, G.; Okuda, S.; Almeida, M.; LeChatelier, E.; Renault, P.; Pons, N.; Batto, J. M.; Zhang, Z.; Chen, H.; Yang, R.; Zheng, W.; Li, S.; Yang, H.; Wang, J.; Ehrlich, S. D.; Nielsen, R.; Pedersen, O.; Kristiansen, K.; Wang, J., A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* **2012,** *490* (7418), 55-60.

[16] Zhao, S.; Liu, W.; Wang, J.; Shi, J.; Sun, Y.; Wang, W.; Ning, G.; Liu1, R.; Hong, J., Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice. *J Mol Endocrinol* **2017,** *58* (1), 1-14.

[17] Depommier, C.; Everard, A.; Druart, C.; Plovier, H.; Van Hul, M.; Vieira-Silva, S.; Falony, G.; Raes, J.; Maiter, D.; Delzenne, N. M.; de Barsy, M.; Loumaye, A.; Hermans, M. P.; Thissen, J. P.; de Vos, W. M.; Cani, P. D., Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. *Nat. Med.* **2019,** *25* (7), 1096-1103.

[18] Png, C. W.; Linden, S. K.; Gilshenan, K. S.; Zoetendal, E. G.; McSweeney, C. S.; Sly, L. I.; McGuckin, M. A.; Florin, T. H., Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. *Am J Gastroenterol* **2010,** *105* (11), 2420-8.

[19] Zhai, R.; Xue, X.; Zhang, L.; Yang, X.; Zhao, L.; Zhang, C., Strain-Specific Anti-inflammatory Properties of Two Akkermansia muciniphila Strains on Chronic Colitis in Mice. *Front Cell Infect Microbiol* **2019,** *9*, 239.

[20] Wang, L.; Christophersen, C. T.; Sorich, M. J.; Gerber, J. P.; Angley, M. T.; Conlon, M. A., Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism. *Appl Environ Microbiol* **2011,** *77* (18), 6718-21.

[21] Candela, M.; Rampelli, S.; Turroni, S.; Severgnini, M.; Consolandi, C.; Bellis, G. D.; Masetti, R.; Ricci, G.; Pession, A.; Brigidi, P., Unbalance of intestinal microbiota in atopic children. *BMC Microbiol.* **2012,** *12* (95), 2-9.

[22] Blacher, E.; Bashiardes, S.; Shapiro, H.; Rothschild, D.; Mor, U.; Dori-Bachash, M.; Kleimeyer, C.; Moresi, C.; Harnik, Y.; Zur, M.; Zabari, M.; Brik, R. B.; Kviatcovsky, D.; Zmora, N.; Cohen, Y.; Bar, N.; Levi, I.; Amar, N.; Mehlman, T.; Brandis, A.; Biton, I.; Kuperman, Y.; Tsoory, M.; Alfahel, L.; Harmelin, A.; Schwartz, M.; Israelson, A.; Arike, L.; Johansson, M. E. V.; Hansson, G. C.; Gotkine, M.; Segal, E.; Elinav, E., Potential roles of gut microbiome and metabolites in modulating ALS in mice. *Nature* **2019,** *572* (7770), 474-480.

[23] Barcena, C.; Valdes-Mas, R.; Mayoral, P.; Garabaya, C.; Durand, S.; Rodriguez, F.; Fernandez-Garcia, M. T.; Salazar, N.; Nogacka, A. M.; Garatachea, N.; Bossut, N.; Aprahamian, F.; Lucia, A.; Kroemer, G.; Freije, J. M. P.; Quiros, P. M.; Lopez-Otin, C., Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. *Nat. Med.* **2019,** *25* (8), 1234-1242.

[24] Olson, C. A.; Vuong, H. E.; Yano, J. M.; Liang, Q. Y.; Nusbaum, D. J.; Hsiao, E. Y., The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. *Cell* **2018,** *173* (7), 1728-1741 e13.

[25] Li, J.; Zhao, F.; Wang, Y.; Chen, J.; Tao, J.; Tian, G.; Wu, S.; Liu, W.; Cui, Q.; Geng, B.; Zhang, W.; Weldon, R.; Auguste, K.; Yang, L.; Liu, X.; Chen, L.; Yang, X.; Zhu, B.; Cai, J., Gut microbiota dysbiosis contributes to the development of hypertension. *Microbiome* **2017,** *5* (1), 14.

[26] Routy, B.; Chatelier, E. L.; Derosa, L.; Duong, C. P. M.; Alou, M. T.; Daillère, R.; Fluckiger, A.; Messaoudene, M.; Rauber, C.; Roberti, M. P.; Fidelle, M., Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. *Science* **2018,** *259*, 91-97.

[27] Ijssennagger, N.; Belzer, C.; Hooiveld, G. J.; Dekker, J.; van Mil, S. W.; Muller, M.; Kleerebezem, M.; van der Meer, R., Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon. *Proc Natl Acad Sci U S A* **2015,** *112* (32), 10038-43.

[28] Sanna, S.; van Zuydam, N. R.; Mahajan, A.; Kurilshikov, A.; Vich Vila, A.; Võsa, U.; Mujagic, Z.; Masclee, A. A. M.; Jonkers, D. M. A. E.; Oosting, M.; Joosten, L. A. B.; Netea, M. G.; Franke, L.; Zhernakova, A.; Fu, J.; Wijmenga, C.; McCarthy, M. I., Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. *Nat. Genet.* **2019,** *51* (4), 600-605.

[29] Guo, X.; Zhang, J.; Wu, F.; Zhang, M.; Yi, M.; Peng, Y., Different subtype strains of Akkermansia muciniphila abundantly colonize in southern China. *J. Appl. Microbiol.* **2016,** *120* (2), 452-9.

[30] Marcial-Coba, M. S.; Saaby, L.; Knochel, S.; Nielsen, D. S., Dark chocolate as a stable carrier of microencapsulated Akkermansia muciniphila and Lactobacillus casei. *FEMS Microbiol. Lett.* **2019,** *366* (2).

[31] Derrien, M.; Collado, M. C.; Ben-Amor, K.; Salminen, S.; de Vos, W. M., The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. *Appl Environ Microbiol* **2008,** *74* (5), 1646-8.

[32] Bharti, S. K.; Krishnan, S.; Kumar, A.; Gupta, A. K.; Ghosh, A. K.; Kumar, A., Mechanism-based antidiabetic activity of Fructo- and isomalto-oligosaccharides: Validation by in vivo, in silico and in vitro interaction potential. *Process Biochem.* **2015,** *50* (2), 317-327.

[33] Li, Z.-t.; Zhu, L.; Zhang, W.-l.; Zhan, X.-b.; Gao, M.-j., New dynamic digestion model reactor that mimics gastrointestinal function. *Biochem. Eng. J.* **2020,** *154*.

[34] Ruan, S.; Luo, J.; Li, Y.; Wang, Y.; Huang, S.; Lu, F.; Ma, H., Ultrasound-assisted liquid-state fermentation of soybean meal with Bacillus subtilis: Effects on peptides content, ACE inhibitory activity and biomass. *Process Biochem.* **2020,** *91*, 73-82.

[35] Ramasamy, U. S.; Venema, K.; Schols, H. A.; Gruppen, H., Effect of soluble and insoluble fibers within the in vitro fermentation of chicory root pulp by human gut bacteria. *J. Agric. Food Chem.* **2014,** *62* (28), 6794-6802.

[36] Chia, L. W.; Hornung, B. V. H.; Aalvink, S.; Schaap, P. J.; de Vos, W. M.; Knol, J.; Belzer, C., Deciphering the trophic interaction between Akkermansia muciniphila and the butyrogenic gut commensal Anaerostipes caccae using a metatranscriptomic approach. *Antonie Van Leeuwenhoek* **2018,** *111* (6), 859-873.

[37] Belzer, C.; Chia, L. W.; Aalvink, S.; Chamlagain, B.; Piironen, V.; Knol, J.; de Vos, W. M., Microbial Metabolic Networks at the Mucus Layer Lead to Diet-Independent Butyrate and Vitamin B12 Production by Intestinal Symbionts. *mBio* **2017,** *8* (5).

[38] Ottman, N.; Davids, M.; Suarez-Diez, M.; Boeren, S.; Schaap, P. J.; Martins Dos Santos, V. A. P.; Smidt, H.; Belzer, C.; de Vos, W. M., Genome-Scale Model and Omics Analysis of Metabolic Capacities of Akkermansia muciniphila Reveal a Preferential Mucin-Degrading Lifestyle. *Appl Environ Microbiol* **2017,** *83* (18).

[39] Wang, M.; Zhang, X. Y.; Guo, R. R.; Cai, Z. P.; Hu, X. C.; Chen, H.; Wei, S.; Voglmeir, J.; Liu, L.,

Cloning, purification and biochemical characterization of two beta-N-acetylhexosaminidases from the mucin-degrading gut bacterium Akkermansia muciniphila. *Carbohydr Res* **2018,** *457,* 1-7.

[40] Collado, M. C.; Derrien, M.; Isolauri, E.; de Vos, W. M.; Salminen, S., Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. *Appl Environ Microbiol* **2007,** *73* (23), 7767-70.

[41] Ouwerkerk, J. P.; van der Ark, K. C. H.; Davids, M.; Claassens, N. J.; Finestra, T. R.; de Vos, W. M.; Belzer, C., Adaptation of Akkermansia muciniphila to the Oxic-Anoxic Interface of the Mucus Layer. *Appl Environ Microbiol* **2016,** *82* (23), 6983-6993.

[42] Reid, D. T.; Eller, L. K.; Nettleton, J. E.; Reimer, R. A., Postnatal prebiotic fibre intake mitigates some detrimental metabolic outcomes of early overnutrition in rats. *Eur J Nutr* **2016,** *55* (8), 2399-2409.

[43] Everard., A.; Lazarevic., V.; Derrien., M.; Girard., M.; Muccioli., G. G.; Neyrinck., A. M.; Possemiers., S.; Holle., A. V., Responses of Gut Microbiota and Glucose and Lipid Metabolism to Prebiotics in Genetic Obese and Diet-Induced Leptin-Resistant Mice. *Diabetes* **2011,** *60,* 2775-2786.

[44] Zhou, Z. Y.; Ren, L. W.; Zhan, P.; Yang, H. Y.; Chai, D. D.; Yu, Z. W., Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling. *Acta Pharmacol Sin* **2016,** *37* (8), 1063-75.

[45] Lee, H.; Ko, G., Effect of metformin on metabolic improvement and gut microbiota. *Appl Environ Microbiol* **2014,** *80* (19), 5935-43.

[46] Anhe, F. F.; Nachbar, R. T.; Varin, T. V.; Vilela, V.; Dudonne, S.; Pilon, G.; Fournier, M.; Lecours, M. A.; Desjardins, Y.; Roy, D.; Levy, E.; Marette, A., A polyphenol-rich cranberry extract reverses insulin resistance and hepatic steatosis independently of body weight loss. *Mol Metab* **2017,** *6* (12), 1563-1573.

[47] Anhe, F. F.; Roy, D.; Pilon, G.; Dudonne, S.; Matamoros, S.; Varin, T. V.; Garofalo, C.; Moine, Q.; Desjardins, Y.; Levy, E.; Marette, A., A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. *Gut* **2015,** *64* (6), 872-83.

[48] Roopchand., D. E.; Carmody., R. N.; Kuhn., P.; Moskal., K.; Rojas-Silva., P.; Turnbaugh., P. J.; Raskin, I., Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet–Induced Metabolic Syndrome. *Diabetes* **2015,** *64,* 2847-2858.

[49] Anhe, F. F.; Pilon, G.; Roy, D.; Desjardins, Y.; Levy, E.; Marette, A., Triggering Akkermansia with dietary polyphenols: A new weapon to combat the metabolic syndrome? *Gut Microbes* **2016,** *7* (2), 146-53.

[50] Alard, J.; Lehrter, V.; Rhimi, M.; Mangin, I.; Peucelle, V.; Abraham, A. L.; Mariadassou, M.; Maguin, E.; Waligora-Dupriet, A. J.; Pot, B.; Wolowczuk, I.; Grangette, C., Beneficial metabolic effects of selected probiotics on diet-induced obesity and insulin resistance in mice are associated with improvement of dysbiotic gut microbiota. *Environ. Microbiol.* **2016,** *18* (5), 1484-97.

[51] Martinez-Gutierrez, F.; Ratering, S.; Juárez-Flores, B.; Godinez-Hernandez, C.; Geissler-Plaum, R.; Prell, F.; Zorn, H.; Czermak, P.; Schnell, S., Potential use of Agave salmiana as a prebiotic that stimulates the growth of probiotic bacteria. *Lwt* **2017,** *84,* 151-159.

[52] Caesar, R.; Tremaroli, V.; Kovatcheva-Datchary, P.; Cani, P. D.; Backhed, F., Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling. *Cell Metab* **2015,** *22* (4), 658-68.

[53] Liebisch, G.; Ecker, J.; Roth, S.; Schweizer, S.; Ottl, V.; Schott, H. F.; Yoon, H.; Haller, D.; Holler,

E.; Burkhardt, R.; Matysik, S., Quantification of Fecal Short Chain Fatty Acids by Liquid
Chromatography Tandem Mass Spectrometry-Investigation of Pre-Analytic Stability. *Biomolecules*
2019, *9* (4).
[54] Zhou, L.; Xie, M.; Yang, F.; Liu, J., Antioxidant activity of high purity blueberry anthocyanins and
the effects on human intestinal microbiota. *Lwt* **2020,** *117*.

List of Table

Table 1 Comparative analysis of relative thickness and diameter of *A. muciniphila* outer

membrane on different media under dynamic culture

Note: a: Relative thickness of the outer membrane of *A. muciniphila,* b: Diameter of *A.*

muciniphila. The brain heart infusion broth (BHI), porcine mucin (PM), human mucin (HM),

BHI+ porcine mucin (BPM), and BHI+ human mucin (BHM). The data are shown as the

mean $\pm$ SD (n = 4) and analyzed using one-way ANOVA with Tukey's test, $*p < 0.05$, $**p <$

0.01.

.

Figure-1

Figure-2

Figure-3

Figure-4

Figure-5

Figure-6

TEM

SEM

Table

Table 1 Comparative analysis of relative thickness and diameter of *A. muciniphila* outer membrane on different media under dynamic culture

Tukey's multiple comparisons test	Mean 1	Mean 2	Summary	Adjusted P Value
a:BHI vs. PM	70.66	101.2	*	0.0159
a:BHI vs. HM	70.66	104.5	**	0.0072
a:BHI vs. BPM	70.66	71.46	ns	>0.9999
a:BHI vs. BHM	70.66	72.11	ns	>0.9999
a:PM vs. HM	101.2	104.5	ns	0.9934
a:PM vs. BPM	101.2	71.46	*	0.0177
a:PM vs. BHM	101.2	72.11	*	0.0152
a:HM vs. BPM	104.5	71.46	**	0.008
a:HM vs. BHM	104.5	72.11	**	0.0068
a:BPM vs. BHM	72.11	72.11	ns	>0.9999
b:BHI vs. PM	871	985	*	0.0137
b:BHI vs. PM	871	999.3	**	0.0035
b:BHI vs. BPM	871	980	*	0.0136
b:BHI vs. BHM	871	971.7	*	0.0214
b:PM vs. HM	985	999.3	ns	0.4533
b:PM vs. BPM	985	980	ns	0.9623
b:PM vs. BHM	985	971.7	ns	0.589
b:HM vs. BPM	999.3	980	ns	0.5442
b:HM vs. BHM	999.3	971.7	ns	0.3824
b:BPM vs. BHM	980	971.7	ns	0.1124